The shadow of generic rivalry has consistently loomed over copyright’s blockbuster drug, Viagra, triggering questions about the prospects of similar drug portfolios. While initial times saw substantial gains, the exclusivity lapse has allowed the way for less expensive substitutes, potentially lowering revenue and posing a real danger for investo